Replies to post #157942 on Biotech Values

[iwfal]

GERN INCY

the data from the Jakafi trials suggest that mutant JAK allele burden is not a predictor of efficacy.

I haven't seen any such analysis tying allele burden to probability of symptom reduction on jakafi. ? But perhaps you are thinking of the fact that jakafi works even on patients without jak mutation? (Note that it works less well in mJak-negative)

PS I find the MF treatment field interesting in that it is pretty clear that hydroxyurea works fairly well and yet there is virtually no well run trial of hydroxyurea in MF. ?

[iwfal]

INCY -

As I recall, the data from the Jakafi trials suggest that mutant JAK allele burden is not a predictor of efficacy.

FWIW the 2010 INCY presentation does, indeed, affirmatively state that allele burden is not a predictor of efficacy.